<?xml version="1.0" encoding="UTF-8"?><xmi:XMI xmlns:cas="http:///uima/cas.ecore" xmlns:xmi="http://www.omg.org/XMI" xmlns:type="http:///org/apache/uima/trials/type.ecore" xmlns:tcas="http:///uima/tcas.ecore" xmi:version="2.0">
    <cas:NULL xmi:id="0"/>
    <tcas:DocumentAnnotation xmi:id="1" sofa="6" begin="0" end="1395" language="x-unspecified"/>
    <type:ORR xmi:id="13" sofa="6" begin="967" end="969"/>
    <type:PFSMean xmi:id="17" sofa="6" begin="986" end="996"/>
    <type:OSMean xmi:id="21" sofa="6" begin="1005" end="1015"/>
    <cas:Sofa xmi:id="6" sofaNum="1" sofaID="_InitialView" mimeType="text" sofaString="BACKGROUND: Patients with upper gastrointestinal cancers have a poor prognosis&#13;&#10;and only few treatment options. The epidermal growth factor receptor (EGFR) and&#13;&#10;vascular endothelial growth factor (VEGF) are valid targets in many solid&#13;&#10;tumours, and they have synergistic effects in preclinical studies.&#13;&#10;METHODS: In this multi-center phase II trial patients with chemoresistant,&#13;&#10;metastatic upper gastrointestinal cancer were treated with erlotinib (150 mg&#13;&#10;daily) and bevacizumab (10 mg/kg every two weeks). Primary endpoint was overall&#13;&#10;response rate (ORR). Secondary endpoints were progression free survival (PFS),&#13;&#10;overall survival (OS), toxicity and biomarker correlates. Plasma samples were&#13;&#10;analysed for EGFR and angiogenesis related markers using quantitative&#13;&#10;immunoassays.&#13;&#10;RESULTS: One hundred and two patients were enrolled in the trial between June&#13;&#10;2006 and October 2007. The most common toxicities were skin reaction, diarrhoea, &#13;&#10;and fatigue. ORR was 6%, median PFS was 2.2 months, and OS 4.3 months. Low&#13;&#10;concentration of urokinase plasminogen activator receptor (uPAR) domain I was&#13;&#10;correlated to longer PFS and OS.&#13;&#10;DISCUSSION: The combination of erlotinib and bevacizumab is well tolerated,&#13;&#10;however, with low clinical activity in patients with chemoresistant UGI cancer.&#13;&#10;Some patients do benefit from the therapy, and uPAR forms are potential&#13;&#10;biomarkers in these patients."/>
    <cas:View sofa="6" members="1 13 17 21"/>
</xmi:XMI>
